Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
07 Octubre 2024 - 3:05PM
Business Wire
Global leader with proven financial,
operational, and commercial expertise joins Nuvation Bio as the
company prepares to transition into a commercial-stage
organization
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global
biopharmaceutical company tackling some of the greatest unmet needs
in oncology, today announced the appointment of Philippe Sauvage as
Chief Financial Officer (CFO).
Mr. Sauvage brings over 20 years of global leadership experience
in finance, operations, and commercialization within healthcare and
biopharmaceutical organizations. Most recently, as Global Head of
Operations and Access at Sanofi, he oversaw strategic segments
including commercial systems, multichannel strategy, and market
access—key factors in supporting market growth and product
launches. Mr. Sauvage previously served as CFO for Sanofi-Genzyme
and Sanofi North America, where he led the financial operations for
all U.S. entities in a $14 billion region. Concurrently, he steered
the company’s Global Specialty Care business through a period of
rapid transformation, resulting in double-digit growth. Earlier in
his career, he served as CFO of Sanofi’s highly diversified $5
billion JPAC region and was the CFO for Japan, the organization’s
second-largest commercial market. Mr. Sauvage also held the role of
Chief Economic and Financial Officer at Assistance Publique
Hôpitaux de Paris, the largest French public health institution and
university hospital serving Paris and surrounding areas, with more
than 100,000 employees and a €7 billion in revenue. Additionally,
he held multiple leadership positions at the French Ministry of
Health including Head of the Health Products Department, which
managed the reimbursement of €30 billion in health products in
France.
“We are excited to welcome Philippe to Nuvation Bio at such an
important stage of our evolution,” said David Hung, M.D., Founder,
President, and Chief Executive Officer of Nuvation Bio. “Philippe
has successfully driven growth and led finance and operations teams
across U.S., European, and Asian markets. Philippe’s uniquely broad
skillset is reflected in his senior positions in pharmaceutical,
hospital and government organizations. His strategic vision and
insights that span finance and operations, to commercial strategy
and marketing, to government and hospital reimbursement and market
access, will be invaluable as we transition to a commercial-stage
organization in 2025.”
“I am thrilled to join Nuvation Bio as the team prepares for the
potential commercialization of taletrectinib and advances its
differentiated oncology pipeline,” said Mr. Sauvage. “I look
forward to working alongside David and the entire team to deliver
better treatment options to people living with difficult-to-treat
cancers.”
Mr. Sauvage holds a Research Masters in Macroeconomics from
Panthéon-Sorbonne University in Paris. He also holds an M.S. in
Engineering from École Polytechnique and completed an elite civil
servant education in Corps des Mines at Mines ParisTech.
About Nuvation Bio
Nuvation Bio is a late clinical-stage, global biopharmaceutical
company tackling some of the greatest unmet needs in oncology by
developing differentiated and novel product candidates. Nuvation
Bio’s portfolio of development candidates includes taletrectinib
(ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET).
Nuvation Bio was founded in 2018 by biopharma industry veteran
David Hung, M.D., who previously founded Medivation, Inc., which
brought to patients one of the world’s leading prostate cancer
medicines. Nuvation Bio has offices in New York, San Francisco,
Boston, and Shanghai. For more information, please visit
www.nuvationbio.com and follow us on LinkedIn.
Forward Looking Statements
Certain statements included in this press release that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
sometimes accompanied by words such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”
“would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,”
“outlook” and similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
These forward-looking statements include, but are not limited to,
our expectations and timing of establishing a commercial
organization. These statements are based on various assumptions,
whether or not identified in this press release, and on the current
expectations of the management team of Nuvation Bio and are not
predictions of actual performance. These forward-looking statements
are subject to a number of risks and uncertainties that may cause
actual results to differ from those anticipated by the
forward-looking statements, including but not limited to the
challenges associated with conducting drug discovery and initiating
or conducting clinical trials due to, among other things,
difficulties or delays in the regulatory process, enrolling
subjects or manufacturing or acquiring necessary products; the
emergence or worsening of adverse events or other undesirable side
effects; risks associated with preliminary and interim data, which
may not be representative of more mature data; competitive
developments; and establishing commercial capabilities. Risks and
uncertainties facing Nuvation Bio are described more fully in its
Form 10-Q filed with the SEC on August 5, 2024, under the heading
“Risk Factors,” and other documents that Nuvation Bio has filed or
will file with the SEC. You are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date of this press release. Nuvation Bio disclaims any
obligation or undertaking to update, supplement or revise any
forward-looking statements contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241007470241/en/
Nuvation Bio Investor Contact: ir@nuvationbio.com
Nuvation Bio Media Contact: media@nuvationbio.com
Panacea Acquisition (NYSE:NUVB)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Panacea Acquisition (NYSE:NUVB)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024